The first meeting of the US Food and Drug Administration’s Genetic Metabolic Diseases Advisory Committee will be heavy on temporary voting members, several of whom are veterans of the adcomm process.
Thirteen of 16 voting members at the 2 August meeting on Zevra’s Denmark A/S’ arimoclomol are temporary members, including the...





